X4 Pharmaceuticals Files 8-K on Shareholder Vote Matters

TL;DR

X4 Pharma filed an 8-K on shareholder vote matters. Keep an eye on governance.

AI Summary

X4 Pharmaceuticals, Inc. filed an 8-K on June 11, 2024, reporting on matters submitted to a vote of security holders as of June 10, 2024. The company, formerly known as Arsanis, Inc., is incorporated in Delaware and is in the biological products sector.

Why It Matters

This filing indicates that X4 Pharmaceuticals is engaging in corporate governance activities, specifically related to decisions requiring shareholder approval, which can impact the company's strategic direction and operations.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not inherently present new financial or operational risks.

Key Players & Entities

• X4 Pharmaceuticals, Inc. (company) — Registrant
• Arsanis, Inc. (company) — Former company name
• June 10, 2024 (date) — Date of earliest event reported
• June 11, 2024 (date) — Date of report
• 001-38295 (other) — Commission File Number
• 27-3181608 (other) — IRS Employer Identification No.
• 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market

Filing Documents

• xfor-20240610.htm (8-K) — 41KB
• 0001628280-24-027680.txt ( ) — 168KB
• xfor-20240610.xsd (EX-101.SCH) — 2KB
• xfor-20240610_lab.xml (EX-101.LAB) — 23KB
• xfor-20240610_pre.xml (EX-101.PRE) — 13KB
• xfor-20240610_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 10, 2024, X4 Pharmaceuticals Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"), at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. Proposal 1 - Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows: Nominees For Withheld Broker Non-Votes David McGirr, M.B.A. 83,110,008 11,137,060 36,561,395 Paula Ragan, Ph.D. 93,318,699 928,369 36,561,395 Michael S. Wzyga 83,840,957 10,406,111 36,561,395 Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes cast were as follows: For Against Abstain Broker Non-Votes 129,116,244 620,394 1,071,825 — Proposal 3 – Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation The Company's stockholders approved, by a non-binding "say-on-pay" vote, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the Annual Meeting. The votes cast were as follows: For Against Abstain Broker Non-Votes 89,159,259 4,443,024 644,785 36,561,395

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: June 11, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR